Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood|December 16, 2021
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaMahmoud R Gaballa, Pinaki Banerjee, Denái R Milton, et al.
Haematologica|June 4, 2026
Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemiaJennifer Miatech, Denái R Milton, Mahmoud R Gaballa, et al.
British Journal of Haematology|March 30, 2025
Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant responseOren Pasvolsky, Muhammad Bilal Abid, Denái R Milton, et al.
Leukemia & Lymphoma|October 23, 2021
Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenanceMahmoud R Gaballa, Junsheng Ma, Mark R Tanner, et al.
Bone Marrow Transplantation|May 6, 2022
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myelomaMahmoud R Gaballa, Junsheng Ma, Mikael Rauf, et al.
Blood Advances|April 8, 2025
Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucelSatabdi Saha, Lubna Rehman, Abdur Rehman, et al.
Oncotarget|September 4, 2016
Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancerAmanda R Oran, Clare M Adams, Xiao-Yong Zhang, et al.
Blood|July 7, 2026
Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple MyelomaMinghao Dang, Luz Yurany Moreno Rueda, Maria Jose Acevedo Calado, et al.
Blood Advances|August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell LeukemiaGliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Pageof 3